Is Nintedanib on the market?

Nintedanib (Nintedanib) is a small molecule kinase inhibitor indicated for the treatment of pulmonary fibrosis, systemic sclerosis-related interstitial lung disease, and non-small cell lung cancer (NSCLC). It was first approved for use in the United States in 2014 and falls within the scope of treatment options for idiopathic pulmonary fibrosis. Nintedanib was approved for marketing bythe European Medicines Agency (EMA) in 2015. It is considered that its benefits outweigh its risks.

Nintedanib is one of only two disease-modifying therapies currently available for this condition (the other is pirfenidone), and is therefore used as first-line treatment after diagnosis to slow the progressive loss of lung function. As a chemotherapy drug for non-small cell lung cancer, nintedanib is used in combination with docetaxel (Docetaxel, ) and is reserved for patients who have tried first-line chemotherapy but failed. Nintedanib was approved by the National Medical Products Administration for marketing in China in in 2022. It is sold under the name of nintedanib ethanesulfonate soft capsules.

The original nintedanib drug marketed in China has entered the scope of Class B medical insurance, but reimbursement is limited to patients who meet the indications. Specifications The price of each box of 150mg*30 tablets may be more than 4,000 yuan. Nintedanib Original drug available overseas has Turkish version and Indian version, specificationsThe price of 150mg*60 capsules per box may be more than 5,000 RMB (the price may fluctuate due to the exchange rate). There are also nintedanib generic drugs produced overseas in other countries. For example, the price of 150mg*30 capsules produced by BDR Pharmaceutical Factory in India may be several hundred yuan per box (the price may fluctuate due to exchange rates). Its pharmaceutical ingredients are basically the same as those of the original drugs sold domestically and abroad.